Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
Reuters10/15/2026Neutral
DXCM
DexCom IncNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$32.47B
P/E Ratio
34.14
EPS
$2.52
Beta
1.48
52W High
$92.59
52W Low
$54.11
50-Day MA
$87.49
200-Day MA
$73.87
Dividend Yield
—
Profit Margin
20.10%
Forward P/E
28.25
PEG Ratio
1.35
About DexCom Inc
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Fundamentals
| Revenue (TTM) | $4.97B |
| Gross Profit (TTM) | $3.10B |
| EBITDA | $1.40B |
| Operating Margin | 24.30% |
| Return on Equity | 38.50% |
| Return on Assets | 10.30% |
| Revenue/Share (TTM) | $12.87 |
| Book Value | $6.95 |
| Price-to-Book | 12.63 |
| Price-to-Sales (TTM) | 6.53 |
| EV/Revenue | 6.57 |
| EV/EBITDA | 20.93 |
| Quarterly Earnings Growth (YoY) | 43.60% |
| Quarterly Revenue Growth (YoY) | 13.10% |
| Shares Outstanding | $377.36M |
| Float | $376.00M |
| % Insiders | 0.26% |
| % Institutions | 106.43% |
Historical Volatility
HV 10-Day
40.58%
HV 20-Day
29.30%
HV 30-Day
29.60%
HV 60-Day
37.36%
HV Rank
23.0%
Volatility is currently expanding
Analyst Ratings
Consensus ($96.46 target)
3
Strong Buy22
Buy3
HoldLatest News
Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine (NEJM), providing rigorous evidence of the significant benefits of continuous glucose monitoring (CGM) for adults with Type 2 diabetes not on insulin. CONNECT participants using Dexcom G7 experienced an average 1.6% A1C reduction from a mean baseline of 8.8%,.
Business Wire10/14/2026Neutral
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DexCom's strong margins, G7 15-day rollout and promising pipeline support its growth outlook, but factory ramp-up costs, forex and input-price pressures pose risks.
Zacks Investment Research10/13/2026Neutral
Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
SAN DIEGO--(BUSINESS WIRE)--DEXCOM, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes.Now in its fifth year, this marks the program's largest and most expansive roster to date, featuring 27 college athletes, 12 new and 15 returning, across 13 sports. The expansion is backed by new research showing that programs l.
Business Wire10/6/2026Neutral
DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care
Dexcom sees room to expand CGM adoption as low awareness, reimbursement hurdles and rising GLP-1 use create new opportunities in Type 2 diabetes.
Zacks Investment Research10/2/2026Positive
Here's Why DexCom (DXCM) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research9/29/2026Positive
Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
MILAN--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today released its “Dexcom State of Type 2 Report: Global Access and Attitudes to Diabetes Technology” in advance of the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28-Oct. 2. The company also announced a partnership to become the official continuous glucose monitor of Team Novo Nordisk. Dexcom releases 2026 edition of its State of Type 2 Repo.
Business Wire9/28/2026Neutral
Oura's $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
Oura Inc. NASDAQ: OURA launched its roadshow on Sept. 21, 2026, targeting a Nasdaq debut under the ticker OURA during the week of Sept.
MarketBeat9/22/2026Neutral
Dexcom Promotes Jereme Sylvain to Chief Operating Officer
SAN DIEGO--(BUSINESS WIRE)--Dexcom Promotes Jereme Sylvain to Chief Operating Officer.
Business Wire9/14/2026Neutral
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and competition risks.
Zacks Investment Research9/14/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DXCM and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 10/17/2026